• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Bandai Namco Holdgs Inc
Cisco Systems
Santen Pharm CO ADR
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medicenna Thera Corp (TSX:MDNA)

0.4100 UNCHANGED
Delayed Quote Updated: 3:51 PM EDT, Oct 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.4100
Bid (Size) 0.4050 (10)
Ask (Size) 0.4200 (10)
Prev. Close 0.4100
Today's Range 0.4100 - 0.4100
52wk Range 0.3350 - 1.970
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference
Today 7:00 EDT
MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and simultaneously inhibit IL-2 and IL-15 signaling to modulate an overactive immune system 
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
October 05, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire

Performance

52-Week Range 79.2% below 52-week high
0.4100
0.3452W Low 1.9752W High
1 Week 8.9% below 1-week high
0.391W Low 0.451W High

Medicenna Thera Corp (MDNA) traded between $0.34 and $1.97 over the past 52 weeks and last traded at $0.41, 79.2% below its 52-week high. Over the past week it ranged between $0.39 and $0.45.

Past 12 Months
-6.8%
-3.5%
+17.1%
-30.5%
-59.0%
-56.4%
1W -$0.03
1M -$0.02
3M +$0.06
6M -$0.18
YTD -$0.59
1Y -$0.53

MDNA was -56.4% over the past year, -30.5% over six months, -59.0% year to date, -6.8% in the last week.

12 Months vs Market
MDNA
-56.4%
DIA
+12.3%
SPY
+13.8%
QQQ
+15.9%
IWM
+11.8%

Over the past 12 months MDNA returned -56.4% versus DIA (Dow) +12.3%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +15.9% and IWM (Russell 2000) +11.8%.

Volume & Liquidity
1W
54.1K
1M
48.3K
3M
46.2K
6M
71.0K
YTD
83.7K
1Y
96.2K

MDNA's 3-month average daily volume is 46.2K.

More News

Read More
News headline image
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
October 01, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
September 24, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 03, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
August 14, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
June 26, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
June 11, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
June 03, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
May 12, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
April 30, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 14, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
April 09, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
March 18, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Announces Participation in Upcoming Conferences
February 18, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
February 13, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Announces Changes to Board Composition
February 13, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
January 15, 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
December 10, 2025
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
December 09, 2025
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
November 13, 2025
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
November 06, 2025
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
October 23, 2025
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics Announces Participation in Upcoming Conferences
October 20, 2025
From Medicenna Therapeutics Corp.
Via GlobeNewswire
News headline image
Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
October 01, 2025
From Medicenna Therapeutics Corp.
Via GlobeNewswire

Frequently Asked Questions

Is Medicenna Thera Corp publicly traded?
Yes, Medicenna Thera Corp is publicly traded.
What exchange does Medicenna Thera Corp trade on?
Medicenna Thera Corp trades on the Toronto Stock Exchange
What is the ticker symbol for Medicenna Thera Corp?
The ticker symbol for Medicenna Thera Corp is MDNA on the Toronto Stock Exchange
What is the current price of Medicenna Thera Corp?
The current price of Medicenna Thera Corp is 0.4100
When was Medicenna Thera Corp last traded?
The last trade of Medicenna Thera Corp was at 10/21/26 03:51 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap